(Q38853500)

7 September 2017

1 reference

title

Venetoclax: First Global Approval (English)

1 reference

7 September 2017

1

Emma D Deeks

1 reference

7 September 2017

3 June 2016

1 reference

7 September 2017

1 reference

7 September 2017

76

1 reference

7 September 2017

9

1 reference

7 September 2017

979-987

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0596-x

7 September 2017

0 references

cites work

New dimension in therapeutic targeting of BCL-2 family proteins

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0596-X

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

21 January 2018

1 reference

12 December 2020

Bcl-2 family proteins are involved in the signal crosstalk between endoplasmic reticulum stress and mitochondrial dysfunction in tumor chemotherapy resistance.

1 reference

12 December 2020

ABT-199 for chronic lymphocytic leukemia.

1 reference

12 December 2020

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses

1 reference

12 December 2020

10.1007/S40265-016-0596-X

Identifiers

DOI

1 reference

PubMed ID

27260335

Dimensions Publication ID

7 September 2017

0 references

1 reference

PubMed ID

27260335